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Abstract
Obesity development during psychotropic treatments represents a major health issue in
psychiatry. Melanin-concentrating hormone receptor 2 (MCHR2) is a central receptor
involved in energy homeostasis.MCHR2 shares its promoter region withMCHR2-AS1, a
long antisense non-coding RNA. The aim of this study was to determine whether tagging
single nucleotide polymorphisms (tSNPs) ofMCHR2 andMCHR2-AS1 are associated with
the body mass index (BMI) in the psychiatric and in the general population. The influence of
MCHR2 andMCHR2-AS1 tSNPs on BMI was firstly investigated in a discovery psychiatric
sample (n1 = 474). Positive results were tested for replication in two other psychiatric sam-
ples (n2 = 164, n3 = 178) and in two population-based samples (CoLaus, n4 = 5409; GIANT,
n5 = 113809). In the discovery sample, TT carriers of rs7754794C>T had 1.08 kg/m
2 (p =
0.04) lower BMI as compared to C-allele carriers. This observation was replicated in an
independent psychiatric sample (-2.18 kg/m2; p = 0.009). The association of rs7754794C>T
and BMI seemed stronger in subjects younger than 45 years (median of age). In the popula-
tion-based sample, a moderate association was observed (-0.17 kg/m2; p = 0.02) among
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younger individuals (<45y). Interestingly, this association was totally driven by patients
meeting lifetime criteria for atypical depression, i.e. major depressive episodes character-
ized by symptoms such as an increased appetite. Indeed, patients with atypical depression
carrying rs7754794-TT had 1.17 kg/m2 (p = 0.04) lower BMI values as compared to C-allele
carriers, the effect being stronger in younger individuals (-2.50 kg/m2; p = 0.03; interaction
between rs7754794 and age: p-value = 0.08). This study provides new insights on the pos-
sible influence ofMCHR2 and/orMCHR2-AS1 on obesity in psychiatric patients and on the
pathophysiology of atypical depression.
Introduction
Compared to the general population, patients with chronic severe mental disorders have an
estimated shorter life expectancy of 15 to 25 years due to the psychiatric disorder and/or physi-
cal comorbidities (i.e obesity or other metabolic disorders) but also in the use of psychotropic
treatments[1]. Indeed, many antipsychotics, in particular atypical antipsychotics, and some
mood stabilizers and antidepressants are associated with important weight gain[2]. The vari-
ability of weight gain observed in patients sharing similar clinical risk factors (i.e gender, age
and psychotropic treatment)[3], together with the heritability of weight regulation observed in
twin, adoption and family studies[4] support the key role of genetic factors in the development
of obesity. Moreover, recent changes in Western lifestyle (ubiquitous access of industrial/palat-
able food and poor physical activity) strongly increase the influence of genetic risk factors
towards the development of obesity. However, genome-wide association (GWAS) and candi-
date gene studies have only explained a small variance of the body mass index (BMI)[5]. There-
fore, the identification of new genetic predictors for the development of obesity in psychiatric
patients is not only of great interest for a better understanding of the mechanisms underlying
excessive weight increase, but also for the future personalized prescription of psychotropic
drugs.
The regulation of food intake, a major component in energy balance, is achieved in part by
highly specialized hypothalamic neurons that are able to sense and integrate peripheral feeding
cues. The exact mechanisms by which peripheral cues-related signals interact within the hypo-
thalamus to modulate the response are only partially understood. However, in this highly com-
plex system of regulation, some specific pathways have been characterized[6, 7]. The
melanocortin pathway, in the arcuate nucleus of the hypothalamus, is a major axis through
which peripheral peptides and hormones converge and act to modulate the energy balance.
Recent studies have enlightened the involvement of the melanin-concentrating hormone
receptor 2 (MCHR2) in the transduction of central orexigenic signals. More specifically, mela-
nin-concentrating hormone (MCH), the agonist of MCHR2, has been shown to be a critical
hypothalamic regulator involved in energy homeostasis in mammals[8, 9]. Mice lackingMCH
gene have been observed to be lean, having decreased feeding behavior and increased energy
expenditure[10]. Even thoughMCHR2 is not expressed in rodents, a recent study showed that
induction ofMCHR2 expression in mice protected against diet-induced obesity[11]. In
humans,MCH was shown to be expressed in neurons of the lateral hypothalamus, an area that
coincides withMCH receptors sites of expression[9]. Moreover, in a French general popula-
tion, a linkage with childhood obesity was identified on chromosome 6q16.3-q24.2[12] and
two single nucleotide polymorphisms (SNPs) withinMCHR2 were further associated with
childhood obesity[13]. Of note, some atypical antipsychotics have been reported to affect
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neuropeptide hormone levels involved in energy homeostasis[14–16]. Specifically, the expres-
sion ofMCH as well as its receptors may be upregulated during antipsychotic treatments,
which may enhance rewarding aspects of food[17]. Moreover, the first genome scan targeting
obesity as a side effect of antipsychotics has observed an implication of the pro-melanin-con-
centrating hormone (PMCH), the precursor ofMCH[18].
Interestingly, during the preparation of the present study, gene region analyses revealed that
theMCHR2 SNP associated with BMI in a Caucasian population-based sample (i.eMCHR2/
MCHR2-AS1 rs6925272)[13], lies not only in the promoter ofMCHR2 but also in the promoter
of another gene transcribed in an antisense way,MCHR2-AS1 (MCHR2-antisense RNA).
MCHR2-AS1 is a RNA gene affiliated to the long non-coding RNA (lncRNA) class. Although
this class of genes is still poorly understood, recent studies have linked some lncRNAs with the
development of different diseases[19–21].
Because of the high prevalence of obesity, of metabolic abnormalities and of mortality rate
within the psychiatric population, the probable involvement of MCHR2 in the phenotype of
obesity and the absence of studies examining the possible influence of genetic polymorphisms
ofMCHR2 on BMI in psychiatric patients, we examined associations between tagging SNPs of
MCHR2 and ofMCHR2-AS1 with BMI in three independent psychiatric samples treated with
psychotropic drugs that were likely to induce weight (i.e clozapine, olanzapine, quetiapine, ris-
peridone, lithium, valproate, mirtazapine, aripiprazole and/or amisulpride). In order to further
investigate whether these above-mentioned associations are valid in the general population as
well or are only specific to psychiatry, we then attempted to replicate the results in two popula-
tion-based samples, one of which had subjects with psychiatric evaluations.
Results
Demographic and clinical characteristics of three psychiatric Caucasian populations are pre-
sented in S1 Table. In the discovery sample, the prevalence of obesity at the end of the follow-
up was lower (17%) than in both replication samples (39% and 28%), which could in part be
explained by the longer treatment duration in the latter samples. The median age of patients in
the discovery sample was higher (50 years) than in both replication samples (43 and 42 years),
the former sample containing geriatric patients, which is not the case for both replication sam-
ples. In each of these three independent psychiatric samples, almost half of patients gained
more than 5% of initial weight during the current psychotropic treatment (41%, 56% and
51%), with a median duration of treatment of 6, 27 and 35 months, respectively.
MCHR2 andMCHR2-AS1 tagging SNPs are presented in S2 Table. rs9403322 and
rs4559096 deviated from Hardy-Weinberg equilibrium in the discovery sample (p-
values0.05). These two SNPs were therefore not further analyzed. Therefore, a total of twelve
SNPs were analyzed in this study. Minor allele frequencies (MAF) in our combined sample
were comparable to those reported in HapMap (Caucasians).
Associations betweenMCHR2 andMCHR2-AS1 Tagging
Polymorphisms and BMI in the Psychiatric Sample
In the discovery sample, three tagging SNPs ofMCHR2 (i.e.MCHR2 rs4840109,MCHR2
rs2001456 andMCHR2 rs7754794) were significantly associated with BMI, with carriers of the
G allele (for rs4840109), G allele (for rs2001456) and TT genotype (for rs7754794) having
lower BMI values as compared to others, respectively (more details in S3 Table). Multiple com-
parison tests in the discovery sample using the false discovery rate method correcting for 12
independent tests revealed p-corrected-values of 0.04 for each of these three SNPs. The remain-
ingMCHR2 andMCHR2-AS1 tagging SNPs were not associated with BMI.MCHR2
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rs4840109,MCHR2 rs2001456 andMCHR2 rs7754794 were tested for replication in replica-
tion samples 1 and 2. P-values of replication analyses were corrected for 3 independent tests
using false discovery rate correction. Both rs4840109 and rs2001456 were not replicated and
were therefore not considered for further analyses. rs7754794 was significantly associated with
BMI in the replication sample 1, for which carriers of TT genotype had 2.18 kg/m2 lower BMI
as compared to C-allele carriers (pcorrected = 0.009). A significant association was also observed
within the combined sample, with TT carriers having 0.84 kg/m2 lower BMI as compared to
others (pcorrected = 0.02; Table 1). Fig 1 presents the evolution of BMI during psychotropic
treatment in patients of the combined sample according to rs7754794 genotype. In carriers
with the TT genotype, the BMI remained stable over time, whereas the BMI of CC or CT carri-
ers increased along the treatment duration. The difference across genotypes reached the thresh-
old of significance after six months of treatment.
Associations betweenMCHR2 rs7754794C>T and BMI in Age-Stratified
Subgroups of the Combined Sample
The influence of rs7754794 polymorphism on BMI was assessed in age-stratified psychiatric
subgroups of the combined sample (interaction between rs7754794 and age: p-value = 0.08).
Only patients younger than 45 years (the median of age in the psychiatric sample) appeared to
be concerned with this genetic effect on BMI, with carriers of TT genotype having 1.59 kg/m2
lower BMI as compared to others (p = 0.003) (Table 2). Of note, in the discovery sample,
rs7754794-TT carriers younger than 45 years had significantly lower waist circumference
(WC) as compared to others (-4.34 cm; p = 0.02; S4 Table).
MCHR2 andMCHR2-AS1 Tagging SNPs Haplotype Analysis
Four haplotype blocks were observed (S1 Fig). Combinations formed from the first three hap-
lotype blocks did not show any significant association with BMI in the combined psychiatric
sample (data not shown). Regarding the block 4 (withinMCHR2-AS1), by combining SNPs
rs11155243, rs9484646 and rs12214805, four different combinations were formed. Wild-type
carriers for these three SNPs (i.e. GGC, frequency of this combination: 0.5) had 2.02 lower unit
BMI as compared to others (p = 0.04). Age-stratified analyses could not be conducted due to
an insufficient number of observations.
Replication ofMCHR2 rs7754794C>T Association with BMI in
Population-Based Samples
The association ofMCHR2 rs7754794 with BMI was further investigated for replication in two
population-based samples (CoLaus and GIANT) using rs7749425, a proxy of rs7754794 (r2 =
0.97). The rs7754794 association with BMI was not replicated in these samples (Table 3). How-
ever, in CoLaus, age-stratified analyses revealed that individuals younger than 45 years and car-
rying rs7754794-TT had a significantly lower BMI and WC than others. Of note, in order to
avoid bias, the same threshold (i.e. 45 years old) was used both in psychiatric and in popula-
tion-based samples. Age-stratified data were not available in GIANT.
In PsyCoLaus, the subset of CoLaus with psychiatric evaluations, stratifications according
to depression subtypes revealed some differences between atypical and non-atypical subgroups.
Women were more prevalent among those with atypical depression (74%) than among the
other depressives (63%; S5 Table). As expected, in the former subgroup, the proportion of sub-
jects with increased appetite, which is one of the 5 diagnostic criteria for this depression sub-
type, was much higher (41%) than in the latter subgroup (5%). Moreover, subjects with
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Table 1. Association ofMCHR2 rs7754794C>T with BMI in three independent Caucasian psychiatric samples.
MCHR2
rs7754794C>T
Discovery sample n = 441 Replication sample 1 n = 153 Replication sample 2
n = 142
Combined sample n = 736
β (95% CI)
(kg/m2)
p-
value
Ex.
var
(%)
β (95% CI)
(kg/m2)
p-
value
Ex.
var
(%)
β (95% CI)
(kg/m2)
p-
value
Ex.
var
(%)
β (95% CI)
(kg/m2)
p-
value
Ex.
var
(%)
CC/CT ref ref ref ref
TT -1.08
(-2.11–(-)
0.35)
0.04 0.46 -2.18
(-3.87–(-)
1.01)
0.009 2.78 0.79
(-0.81–
3.01)
0.42 -0.84
(-1.52–(-)
0.32)
0.02 0.28
Results were obtained by ﬁtting Generalized Additive Mixed Models for patients, controlling for age, sex, smoking status, current psychotropic drug and
comedications possibly causing weight-gain. β: estimate. p-value: corrected for multiple tests.Ex. var (%): explained variance by the polymorphism, only
calculated for signiﬁcant results. ref: reference.
doi:10.1371/journal.pone.0139155.t001
Fig 1. BMI evolution during psychotropic treatment according to protective or riskMCHR2 rs7754794C>T genotype. Caucasian patients carrying
protective (TT) or risk (CC or CT) rs7754794C>T variant. Median, interquartiles and number of observations for each box are indicated.
doi:10.1371/journal.pone.0139155.g001
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atypical depression were more frequently in a current episode at the moment of the evaluation
than the other subjects with a major depressive disorder (28% versus 13%), which is likely to
explain the higher proportion of antidepressant use (23% versus 13%, respectively). In the Psy-
CoLaus sample, there was no association between rs7754794 and BMI (Table 4). However,
there was an interaction (p = 0.04) between the rs7754794-TT genotype and a lifetime major
depressive episode with DSM-IV atypical depression regarding the BMI. Indeed, among sub-
jects with atypical depression features, those carrying rs7754794-TT had a significantly lower
BMI (-1.17 kg/m2) as compared to C-allele carriers (p = 0.04), whereas the BMI of individuals
with no history of an atypical depression was not influenced by this genetic polymorphism.
Age-stratified analyses revealed that this association was also observed in individuals younger
than 45 years with atypical depression (-2.50 kg/m2; p = 0.03). Of note, no significant associa-
tion was found between rs7754794 and BMI in subjects without lifetime major depressive epi-
sode (data not shown). Finally, no difference of rs7754794 frequency was observed between
subgroups of diagnosis of PsyCoLaus (S6 Table). Subgroups of diagnosis were not available in
the combined sample.
Discussion
The present results suggest a contribution ofMCHR2 and/orMCHR2-AS1 in the regulation of
human body weight, which is consistent with the proposed role of MCH and MCHR2 pathway
in the literature[9] and with the only other genetic study onMCHR2 which reported an associ-
ation ofMCHR2 genetic polymorphism with obesity in the general population[13]. To our
knowledge, this is the first study performed in psychiatric subjects, i.e. a population with a high
prevalence of obesity or overweight phenotypes. Specifically, this study showed a significant
association ofMCHR2/MCHR2-AS1 genetic polymorphisms with BMI in the psychiatric popu-
lation as well as in a psychiatric subgroup of a population-based sample. Moreover, a haplotype
combination of threeMCHR2-AS1 tagging SNPs was also significantly associated with BMI in
the psychiatric population.
Interestingly, the association ofMCHR2 rs7754794 with BMI was only observed in patients
younger than 45 years old. Because a first treatment exposure has been previously described as
an important risk factor for important weight gain[22], it could be hypothesized that age
would be a proxy of first-treatment exposure in younger patients. However, most of the young
patients had already received previous psychiatric drug treatment before inclusion and there
Table 2. Age-stratified analysis forMCHR2 rs7754794C>T association with BMI.
MCHR2 rs7754794C>T Combined sample
n β (95% CI) (kg/m2) p-value Ex. var (%)
Age45 374
CC/CT ref
TT -1.59 (-2.65–(-)0.46) 0.003 1.11
Age>45 366
CC/CT ref
TT -0.23 (-1.09–0.75) 0.35
Results were obtained by ﬁtting Generalized Additive Mixed Models for patients, controlling for age
(whenever appropriate), sex (whenever appropriate), smoking status, current psychotropic drug and
comedications possibly causing weight-gain. β: estimate. Ex. var (%): explained variance by the
polymorphism, only calculated for signiﬁcant results. ref: reference.
doi:10.1371/journal.pone.0139155.t002
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was no association betweenMCHR2 rs7754794 and BMI in a subgroup of the discovery sample
with a newly diagnosed psychiatric disorder (see Supporting information for further details).
Therefore,MCHR2 rs7754794 seems to be associated with BMI in younger patients indepen-
dently of the psychotropic treatment exposure status.MCHR2 has been described as one of the
components acting in the hypothalamic regulation of food intake[23, 24], a system of regula-
tion involved early in the development of obesity. Additionally, age has been found to affect
appetite regulation with elderly individuals having a less efficient hypothalamic regulation of
food intake[25, 26]. These elements may suggest that genetic risk factors involved in the regula-
tion of food intake in young individuals may be more important than in the elderly. Interest-
ingly, replication analyses in the population-based sample (CoLaus) was in accordance with
this hypothesis, where the association betweenMCHR2 genetic polymorphism and BMI was
only significant in younger individuals. Moreover, the only reported study that associated
MCHR2 with obesity also observed an age-dependent genetic susceptibility in obesity, with the
younger being more concerned[13]. The association betweenMCHR2/MCHR2-AS1 with BMI
found in the discovery sample was confirmed in replication sample 1 but not in replication
Table 3. Replication analyses in Caucasian population-based samples.
rs7749425C>T (proxy of
rs7754794C>T)
ALL SUBJECTS 45 years subjects
BMI WC BMI WC
n β (kg/
m2)
p-
value
n β (cm) p-
value
n β (kg/
m2)
p-
value
n β
(cm)
p-
value
GIANT 113809 ref
0.0032 0.47 NA NA NA
CoLaus 5409 ref 5409 ref 1463 ref 1463 ref
-0.0492 0.22 -0.0381 0.34 -0.17 0.02 -0.15 0.04
Results were obtained by using robust regression, adjusted for age and sex. BMI: body mass index; WC: waist circumference. ref: reference (i.e carriers
of the C allele at rs7749425 locus). β: estimate. NA: non applicable.
doi:10.1371/journal.pone.0139155.t003
Table 4. Replication analyses in PsyCoLaus, the subset of CoLaus with psychiatric evaluations.
rs7749425C>T (proxy of
rs7754794C>T)
ALL SUBJECTS 45 years subjects
BMI WC BMI WC
n β (kg/
m2)
p-
value
n β
(cm)
p-
value
n β (kg/
m2)
p-
value
n β
(cm)
p-
value
PsyCoLaus: 3938 ref 3938 ref 907 ref 907 ref
All subjects -0.15 0.42 -0.58 0.26 -0.28 0.38 -1.33 0.13
PsyCoLaus: 1580 ref 1580 ref 404 ref 404 ref
Depression -0.21 0.46 -0.52 0.5 -0.35 0.45 -1.73 0.16
PsyCoLaus: 1127 ref 1127 ref 278 ref 278 ref
Non-atypical depression 0.18 0.56 0.17 0.85 0.37 0.44 -0.36 0.79
PsyCoLaus: 453 ref 453 ref 126 ref 126 ref
Atypical depression -1.17 0.04* 0.12 -2.5 0.03* -5.59 0.05
Results were obtained by using robust regression, adjusted for age and sex. BMI: body mass index; WC: waist circumference. ref: reference (i.e carriers
of the C allele at rs7749425 locus). β: estimate.
*Interaction between atypical depression and rs7749425 signiﬁcant (p = 0.04).
doi:10.1371/journal.pone.0139155.t004
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sample 2. In the latter sample, the positive association between rs7754794 and BMI in patients
older than 45 years may have hampered replication when considering the whole replication
sample 2 (see Supporting information for further details). Additionally, the longer treatment
duration in replication sample 2 (median of 35 months) as compared to the two other samples
(6 and 27 months, respectively) may have also contributed to the observed differences.
Interestingly, within the PsyColaus replication sample, MDD (major depressive disorder)
subtypes stratification revealed that individuals with present or past depression with atypical
features were concerned with the protective effect of rs7754794 on BMI, whereas other individ-
uals (i.e those without depression or those with depression with non-atypical features) were
not. Atypical depression has been characterized by an improved mood in response to positive
events, featuring some symptoms such as an increased appetite, weight gain and hypersomnia
[27]. In PsyCoLaus, the atypical subtype of MDD has been described as a strong predictor of
obesity[28]. Of note, several common biological states linking obesity and depression have
been determined, such as the dysregulation of the hypothalamic-pituitary-adrenocortical axis
[29, 30]. Moreover, theMCH pathway has been involved in both body weight and mood status
regulation in rats[31]. In the present study, no difference of rs7754794 frequency was observed
in the atypical depression subgroup of PsyCoLaus, as compared to others (data not shown),
suggesting thatMCHR2/MCHR2-AS1 variant is not a risk factor for atypical depression but
rather for BMI increase during atypical depression. BMI increase in patients with atypical
depression may result from several factors, including illness symptoms, such as an increased
appetite and/or a sleeping dysregulation. Interestingly,MCH has been associated with the regu-
lation of both atypical depression features in humans[32, 33]. Exploratory association analyses
ofMCHR2 rs7754794 with appetite conducted in the discovery sample and in the atypical
depression subgroup revealed no significant association (see Supporting information for fur-
ther details). It would be interesting to investigate in the future whether this genetic variant is
associated with sleep regulation. Of note,MCHR2 rs7754794 effect on BMI was higher in the
psychiatric population than in replication population-based samples. In addition, positive
results found in the general population appear to be totally driven by the subgroup of subjects
with present or past atypical depression. It can however not be excluded thatMCHR2
rs7754794 does contribute to BMI regulation in other populations, including non psychiatric
individuals as well.
Interestingly,MCHR2 rs7754794 is not only a tagging SNP ofMCHR2, but is also a proxy of
rs6925272 (r2 = 0.97), aMCHR2-AS1 tagging SNP lying in the promoter region of both
MCHR2 andMCHR2-AS1. Therefore, our results could be directly linked with a differential
MCHR2 and/orMCHR2-AS1 genotype-dependent expression. Analyses ofMCHR2 and
MCHR2-AS1 expression have been conducted in peripheral blood mononuclear cells in a sub-
set of the discovery sample. Unfortunately, these two genes were not expressed in these cells
(data not shown). Even when focusing on patients receiving olanzapine, a medication having
been described as a potent inducer of MCH receptor[17], no expression of these two genes
could be detected in peripheral cells (data not shown). Further expression analyses ofMCHR2
andMCHR2-AS1 within their functional tissue are of particular interest and will help to under-
stand their implication in the development of obesity. Regarding the possible biological func-
tion of long antisense non-coding genes, a recent study observed an epigenetic-conducted
transcription of a gene (i.e APOA1; apolipoprotein A1) by a lncRNA in its antisense direction
(APOA1-AS1)[34]. However, further studies are needed to better characterize the role of long
noncoding antisense RNAs in the pathophysiology of obesity.
Several limitations of this study need to be acknowledged. Firstly, this study was restricted
to Caucasian patients and results cannot be extrapolated to other ethnicities. Secondly, we
could not link anyMCHR2 and/orMCHR2-AS1 tagging-variants with their expression to
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functionally validate our hypotheses. Thirdly, we were not able to determine whether the poly-
morphism associated with BMI lies inMCHR2,MCHR2-AS1 or in the promoter region of both
genes. On the other hand, the fact that the results were replicated in one independent sample
and in a psychiatric subgroup of a population-based sample, the latter used as a proof of con-
cept of the polymorphism effect, strengthens the validity of our data.
In conclusion, this is the first genetic study linkingMCHR2 and/orMCHR2-AS1 tagging
polymorphisms and BMI in psychiatric patients under psychotropic treatments. The present
results are in agreement and expand those from the lone study preformed until now, showing a
significant association betweenMCHR2 and BMI in the general population[13]. Moreover, the
significant interaction found betweenMCHR2/MCHR2-AS1 and BMI in population-based
subjects with present and/or previous history of atypical depression but not non-atypical
depression provides new clues to the pathophysiology of atypical depression.
Materials and Methods
Psychiatric Samples
Discovery sample (Lausanne follow-up prospective psychiatric study). Since 2007, a
prospective cohort study is ongoing in the Psychiatric University Hospital of Lausanne includ-
ing 474 Caucasian patients with newly prescribed psychotropic drugs (see Supporting Informa-
tion). Clinical variables and body weight were prospectively recorded at several time points
during the first 12 months of treatment, according to published recommended monitoring
guidelines (i.e before starting the psychotropic treatment and at months 1,2,3,6 and 12)[35].
Replication sample 1 (Geneva retrospective psychiatric study). From 2006 to 2008, a
study was conducted in out-patient psychiatric centers of Geneva University Hospital. 163
Caucasian patients treated for more than 3 months with psychotropic drugs were included (see
Supporting Information).
Replication sample 2 Lausanne retrospective study). From 2010 to 2011, a study was
conducted in two out-patient psychiatric centers of Lausanne (Lausanne University Hospital
and a private psychiatric center). 178 Caucasian patients treated with psychotropic drugs were
recruited (see Supporting Information).
In the three samples, demographic data, history of treatment and comedications were
obtained from medical files. At inclusion, body weight and height were measured with partici-
pants standing without shoes in light clothes. Body weight was measured in kilograms to the
nearest kg. Height was measured to the nearest cm using a height gauge. Body mass index
(BMI) was defined as weight/height2 (kg/m2). BMI values between 25–30 kg/m2 and equal or
higher than 30 kg/m2 were used to define overweight and obese patients, respectively. Psychiat-
ric diagnoses were established by physicians according to the ICD-10 classification. Most
patients had already received other psychotropic treatments before the current treatment. For
patients in replication samples 1 and 2, clinical variables, body weight and height were mea-
sured during the interview, while their previous weight data (i.e. weight before the beginning of
the current treatment and/or weight at different times during the current treatment) were
either collected from medical files or self-reported. Full description of these samples was pub-
lished elsewhere[36]. Written informed consents were obtained from patients or their legal
representatives for the three psychiatric cohorts and these studies were approved by the Ethics
Committee of Geneva and Lausanne University Hospitals.
Population-Based Samples
Results were replicated in two population-based samples: CoLaus/PsyCoLaus, n = 5 409 [37,
38] and Genetic Investigation of ANtropometric Traits (GIANT, n = 123 865)[5].
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CoLaus/PsyCoLaus. Participants aged from 35 to 75 years were recruited between June
2003 and May 2006, as previously described for CoLaus[37]. The assessment included cardio-
vascular risk factors such as body mass index (BMI), fat mass, waist circumference (WC),
blood pressure, blood glucose, triglycerides and high density lipoprotein cholesterol. In addi-
tion, all Caucasians (91% of the sample) underwent a genetic exam (GWAS; n = 5409). All par-
ticipants of CoLaus in the age range of 35 to 66 years were also asked to participate in a
psychiatric evaluation (PsyCoLaus) based essentially on a semi-structured diagnostic interview
[38]. In PsyCoLaus, we could subtype depressive individuals by atypical features according to
the DSM-IV. Combined genetic and psychiatric data were available for 3938 participants. Gen-
otyping for the CoLaus/PsyCoLaus subjects was performed using the Affymetrix GeneChipR
Human Mapping 500K array set. Demographic and clinical characteristics of PsyCoLaus are
shown in results.
Genetic Investigation of ANtropometric Traits (GIANT) consortium. The GIANT con-
sortium performed a meta-analysis of GWAS data with a discovery set of 123 865 individuals
of European ancestry from 46 studies for height [39], BMI [5] and waist-to hip ratio [40].
Genotyping and Candidate Gene Polymorphisms
rs6925272 was first selected based on a previous study[13] and genotyped using Taqman allelic
discrimination assay (ABI PRISM 7000 Sequence Detection System; Applied Biosystems, Rotk-
reuz, Switzerland). Tagging SNPs withinMCHR2 andMCHR2-AS1 where then selected using
HapMap Genome Browser (release #28, NCBI build 36, dbSNP b126). Ten tagging polymor-
phisms withinMCHR2 and twelve withinMHCR2-AS1 were obtained by limiting the search to
SNPs with a minor allele frequency>5% in the Caucasian population and r2 cutoff of 0.8.
MCHR2 tagging SNPs were customized and added to the Illumina 200K cardiometabochip
[41], whereas four among twelveMCHR2-AS1 tagging SNPs were added to the cardiometabo-
chip. Due to technical issues, proxies of SNPs were chosen in some cases (S7 Table). A good
concordance was observed between genotypes obtained using Taqman and those obtained in
the Cardiometabochip.
Statistical Analysis
Associations between tagging SNPs ofMCHR2 and ofMCHR2-AS1 and BMI were first tested
in the discovery sample. Only SNPs significantly associated with BMI were tested for replica-
tion in the two replication psychiatric samples and the population based samples. For the
assessment of association between BMI and tagging SNPs in psychiatric samples, a generalized
additive mixed model (GAMM) was fitted, adjusting for age, gender, smoking status, current
psychotropic drug and comedications potentially inducing weight gain (S8 Table), allowing a
smooth trend for the response in time based on multiple observations for each patient.
GAMMs were fitted using the mgcv package of R, in which parameter uncertainties (confi-
dence intervals and p-values) were computed using 1000 bootstrap replicates with replacement,
performed on patient level. Replication analyses in population-based samples were conducted
using robust regression adjusted for age and sex. P-values of these two-sided models 0.05
were considered as statistically significant. All the analyses were performed using Stata 12 (Sta-
taCorp, College Station TX, USA) and R version 2.13.0 software. Haploview 4.2 [42] was used
to define haplotype blocks and linkage disequilibrium (LD) between differentMCHR2 or
MCHR2-AS1 SNPs (D’ and r2). The haplo.stat package of R was used for haplotype analysis. P-
values were defined using asymptotic chi-squared tests of haplo scores.
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